Project: Research project

Project Details


The Olmsted County Study of Urinary Symptoms and Health Status
among Men is a prospective cohort study of urologic aging in a random sample of
over 2,000 community-dwelling men. This study has made a number of significant
contributions to our understanding of the natural history of signs and symptoms
related to benign prostatic hyperplasia (BPH) that are free from the biases
present in clinical series of patients. These findings, however, are limited to
an initial ten years of follow-up that was funded by Merck Research Labs. Since
BPH is a chronic, progressive disease and complications are manifest over
extended periods, the continued follow-up of this cohort is necessary to accrue
sufficient events to provide long-term risk information. These data are not
presently available but are necessary to make informed clinical decisions.
Furthermore, extending follow-up will increase the precision of estimates of
change in surrogate measures of BPH, providing better insight into what would
be expected in community-dwelling men in the absence of a clinical trial
setting. The continued follow-up also will provide a better understanding of
how serum PSA levels change over time. The specific aims for this application
are designed to expand upon our previous findings with an additional four years
of follow-up using our well-established protocols. We will determine the
14-year progression of clinical (symptoms), physiologic (peak urinary flow
rates) and anatomic (prostate volume) surrogate measures of BPH (Aim 1). We
will examine how these vary together over time (Aim 2) and gather information
on long-term risk of complications and treatment and relate this to the
surrogate measures of BPH (Aim 3). We will also assess the longitudinal changes
in serum PSA levels (Aim 4) in order to increase our understanding of the
relationship between increases in PSA levels and prostate growth in the absence
of cancer. Thus, with the completion of these aims, we will have provided
much-needed insight into the role of surrogate measures of BPH in understanding
the natural history of this condition in the community at large. This
information will prove useful in the design of future clinical trials and
epidemiologic studies. Furthermore, we will have provided information that is
necessary for informed clinical decision making for treatment of BPH.
Effective start/end date9/30/0010/31/11


  • Medicine(all)